Skip to main content
. Author manuscript; available in PMC: 2013 Nov 21.
Published in final edited form as: Oncogene. 2008 Mar 10;27(29):10.1038/onc.2008.49. doi: 10.1038/onc.2008.49

Figure 5. Effects of the mTOR Inhibitor Rapamycin on the Growth of PTEN Transfected Cells.

Figure 5

Panel A) The effects of rapamycin on the growth of PTEN transfected cells were examined by MTT analysis. Panel B). The effects of a constant amount of rapamycin (1 nM) on the doxorubicin IC50s were examined. Upon treatment with rapamycin, the combined doxorubicin IC50s were approximately 60, 47.5, 34.8 and 92.6 nM for the EGFP-c2, PTEN(WT), PTEN(C124S) and PTEN(G129E) cells, whereas in the absence of rapamycin they were approximately 90, 95, 775 and 565 nM respectively. Again, the doxorubicin IC50 in the PTEN(C124S), which lacks both lipid and protein phosphatase activity was affected to the greatest level. The differences in doxorubicin IC50 after treatment with 1 nM between MCF/PTEN(C124S), MCF/PTEN(G129E) and MCF/EGFP-c2 were statistically compared and are indicated by asterisks (***, P<0.001). The differences in doxorubicin IC50 after treatment with 1 nM between MCF/PTEN(C124S) and MCF/PTEN(G129E) were statistically compared and are indicated by asterisks (**, P<0.005). Rapamycin was determined to synergize with doxorubicin by the CalcuSyn program with combination indexes less than one. Rapamycin suppressed the detection of activated p70S6K (T389) in these cells by western blot analysis (data not presented).